Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of two doses of CagriSema versus semaglutide in adults with obesity with or without type 2 diabetes
NL-OMON61415Phase 3Active, not recruiting
- Sponsor
- Novo Nordisk
- Start
- Jul 2026
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
A Phase 3 trial of cagrilintide, semaglutide in obesity, type 2 diabetes mellitus (T2DM), sponsored by Novo Nordisk. Started Jul 2026; status: active, not recruiting.
02
Drugs
cagrilintidesemaglutide
03
Conditions
obesitytype 2 diabetes mellitus (T2DM)
Beyond the preview
Go deeper on NL-OMON61415.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON61415.